Indian bio-economy bigger than $35 billion, reveals ABLE report

While the report released by Association of Biotechnology Led Enterprises (ABLE) at the ongoing BIO International Convention in San Francisco is based on the estimates from government data and other sources, it plans to prepare a more exhaustive report shortly


San Francisco/New Delhi:  According to a Special Report prepared by the Association of Biotechnology-Led Enterprises (ABLE), the India’s fast-growing BioEconomy has crossed the $35.1 billion in 2015. The report was released on the inaugural day of the BIO International Conference at Moscone Convention Center in San Francisco on June 7.

“ This is just an initial estimate and the actual size of the country’s BioEconomy could be actually much more,” said ABLE Chairperson and CMD of Biocon, Dr Kiran Mazumdar-Shaw, while releasing the Special Report at the India Pavilion at the BIO Convention. The BioEconomy report is part of the Make in India Biotechnology Handbook 2016 brought out by ABLE with support from DBT, BIRAC, CII, KBITS, Bangalore BioInnovation Center, Biocon and Syngene.

India has set an ambitious target of achieving a BioEconomy of $ 100 billion by the year 2025.

Dr Shaw released the report along with Ms Holly Vineyard, Assistant Secretary of US Department of Commerce, and Mr Nandamuri Ramakrishna, member of Andhra Pradesh Legislative Assembly and Mr Venkatesan Ashok, the Consul General of India-San Francisco. The opening of the India Pavilion and Handbook release was witnessed by more than 150 delegates from India and other countries at the world’s largest biotechnology industry event.

While the report prepared by ABLE is based on the estimates from government data and other sources, it plans to prepare a more exhaustive report shortly.

ABLE team has been working over the past month to put together the data on India’s BioEconomy and the Make in India Biotech Handbook 2016. The quick estimates were made from various publicly available and government data on export and import of various products that constitute the key elements of the country’s BioEconomy. A more exhaustive report will be prepared in the coming months.

Segment-wise Value of India’s BioEconomy
SEGMENT Sub-segment Retail Vale in $Billion
  Therapeutics 2.2
  Vaccines 3.8
  Diagnostics & Diagnostic services 12.9
BIOAGRI   9.015
  Bt Cotton 9
  Biopesticides/Bio Fertilizers 0.015
  Informatics / Genomics 0.05
  Healthcare IT products/services 4.35
  Enzymes 0.95
  Biofuels 0.95
  CRAMS / CRO 0.9
Total Bio Economy 35.1
(Source:  ABLE estimates from public sources)

Inaugurating the India Pavilion, the ABLE Chairperson Dr Shaw mentioned that this is an exciting time for India’s biotechnology sector. She said the Make in India initiative, the new National Policy on Intellectual Property Rights(IPR), the Start Up Initiative that aims to create more than 10,000 startups in technology sectors in the next few years and general increase in confidence levels were key factors driving the growth of India’s BioEconomy.

The Consul General and Mr Ramakrishna too reiterated these points as the drivers of India’s growth economy.  Summing up the inaugural function, ABLE President and Evolva India CEO, Dr P M Murali said the Indian delegation has arranged a number of conference sessions to highlight recent developments in regulatory regime related biosimilars, clinical trials, the start up ecosystem and other areas of great interest to global investors looking at India for biotech investments.

 (This news piece is based on the inputs provided by Mr Narayanan Suresh, Chief Operating Officer of ABLE).